Brainsway (BWAY) Stock Forecast & Price Target

BrainsWay is supported by a strengthening clinical and commercial thesis, as Deep TMS showed an 83.3% response rate and 50% remission rate in 12 patients with MDD and early-stage Alzheimer’s, while a separate analysis in 89 MDD patients with suicidal ideation found a 70% relative reduction over six weeks. The company is also expanding its addressable market through a new FDA clearance application for comorbid PTSD/MDD backed by real-world data from 462 patients across 11 clinical sites, with an 83.5% PTSD response rate and 52% mean PCL-5 reduction, plus ongoing AUD enrollment and planned neurology studies. Financially, 2Q26 revenue of $17.1M exceeded expectations, full-year 2026 guidance was raised to $68-70M, and the business is gaining scale through a recurring revenue model that is driving sustainability and growth.

BrainsWay is viewed negatively because its valuation depends heavily on a 5.6x sales multiple applied to just $78.5M of forward 12-month revenue, leaving little margin for disappointment if execution falters. The core risks are fundamental: inconsistent commercial execution, slower-than-expected uptake of Deep TMS systems, weak reimbursement or market access expansion, and limited adoption of new indications could all constrain growth despite the ARR-driven model. With ~$62.1M in cash as of mid-2026 and 42.3M ordinary shares outstanding as of mid-2027, the company also faces dilution risk and higher operating expenses if growth does not accelerate.